Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TYK2 is a key regulator of the surveillance of B lymphoid tumors
Dagmar Stoiber, … , Michael Freissmuth, Veronika Sexl
Dagmar Stoiber, … , Michael Freissmuth, Veronika Sexl
Published December 1, 2004
Citation Information: J Clin Invest. 2004;114(11):1650-1658. https://doi.org/10.1172/JCI22315.
View: Text | PDF
Article Oncology

TYK2 is a key regulator of the surveillance of B lymphoid tumors

  • Text
  • PDF
Abstract

Aberrant activation of the JAK-STAT pathway has been implicated in tumor formation; for example, constitutive activation of JAK2 kinase or the enforced expression of STAT5 induces leukemia in mice. We show here that the Janus kinase TYK2 serves an opposite function. Mice deficient in TYK2 developed Abelson-induced B lymphoid leukemia/lymphoma as well as TEL-JAK2–induced T lymphoid leukemia with a higher incidence and shortened latency compared with WT controls. The cell-autonomous properties of Abelson murine leukemia virus–transformed (A-MuLV–transformed) TYK2–/– cells were unaltered, but the high susceptibility of TYK2–/– mice resulted from an impaired tumor surveillance, and accordingly, TYK2–/– A-MuLV–induced lymphomas were easily rejected after transplantation into WT hosts. The increased rate of leukemia/lymphoma formation was linked to a decreased in vitro cytotoxic capacity of TYK2–/– NK and NKT cells toward tumor-derived cells. RAG2/TYK2 double-knockout mice succumbed to A-MuLV–induced leukemia/lymphoma faster than RAG2–/–TYK2+/– mice. This defines NK cells as key players in tumor surveillance in Abelson-induced malignancies. Our observations provide compelling evidence that TYK2 is an important regulator of lymphoid tumor surveillance.

Authors

Dagmar Stoiber, Boris Kovacic, Christian Schuster, Carola Schellack, Marina Karaghiosoff, Rita Kreibich, Eva Weisz, Michaela Artwohl, Olaf C. Kleine, Mathias Muller, Sabina Baumgartner-Parzer, Jacques Ghysdael, Michael Freissmuth, Veronika Sexl

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Effect of TYK2–/– NK/NKT cells on tumor target cells. (A and B) Cytotoxi...
Effect of TYK2–/– NK/NKT cells on tumor target cells. (A and B) Cytotoxicity assay using in vitro_expanded NK/NKT cells of WT (diamonds) and TYK2–/– animals (squares) as effector cells and the TYK2–/– tumor-derived cell line (A) or the TYK2+/– cell line (B) as target cells. Irrespective of the target cells, TYK2–/–-derived NK/NKT cells had a reduced cytolytic ability. Each assay combination was tested at least 3 times. One representative experiment is depicted. (C) Kaplan-Meier plot of TYK2+/– and TYK2–/– mice on a RAG2–/– background after injection of a replication-incompetent A-MuLV retrovirus (n = 14 for TYK2+/– and n = 18 for TYK2–/–). RAG2–/–TYK2–/– animals succumbed significantly earlier to Abelson-induced disease than their RAG2–/–TYK2+/– littermates as determined by a log rank test (P = 0.0027).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts